ArticleBMC global and public health2025
Vaccine confidence and potential implications for new tuberculosis vaccines.
Article in BMC global and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundA lack of general vaccine confidence has been identified as a potential barrier to the introduction of new tuberculosis (TB) vaccines. In the absence of TB-specific vaccine confidence surveys, analysis of general national vaccine confidence data can provide a useful proxy to determine where demand generation strategies may need to be focused ahead of future TB vaccine introductions.
methodsWe analysed 2023 Vaccine Confidence Index (VCI) data from 18 of the 49 countries present on at least one of the three World Health Organisation (WHO) high TB burden lists, and together containing 65% of the global TB burden, to explore overall confidence in vaccines in high TB burden countries. Based on collected answers to three different statements, we categorised responses 1-2 as 'positive' (vaccine confident) and 3-4 as 'negative' (vaccine hesitant) and calculated a total vaccine confidence score using the mean proportion of positive responses across the three statements.
resultsIn 2023, over 80% of respondents in 14 of the 18 countries analysed, and over 60% of respondents in all 18 countries, believed that 'vaccines are important for people of all ages'. India, accounting for around 30% of global TB cases, demonstrated confidence levels exceeding 90%, as did Vietnam, Ethiopia and Sierra Leone. South Africa, the country with the seventh highest TB burden (280,000 incident cases in 2023), Russia and Cameroon exhibited a relatively low vaccine confidence score of 75.5% or lower, signalling a potential area for concern. These countries may require focused awareness-raising and advocacy efforts prior to the rollout of new TB vaccines, though additional research on TB-specific confidence indicators is needed.
conclusionsThis analysis underscores the importance of monitoring vaccine confidence levels to address emerging challenges to maintaining or bolstering the public's trust in vaccination. Our findings could help determine which countries to prioritise for social mobilisation and demand generation efforts to boost vaccine confidence, and thus improve readiness for new TB vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.